GT Biopharma (FRA:OXIA) PEG Ratio: 3.07 (As of Jul. 05, 2026)


FRA:OXIA GT Biopharma Inc FRA:OXIA
21 GF Score
Price €4.77
! 1 Warning Sign
View Full Analysis

What is GT Biopharma PEG Ratio?

GT Biopharma FRA:OXIA 21 PEG Ratio is 3.07 as of Jul. 05, 2026. GuruFocus rates FRA:OXIA with a GF Score™ of 21/100. The stock has 1 warning sign investors should review. Among 95 Biotechnology companies, GT Biopharma ranks better than 92.63% on this metric.

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, GT Biopharma's PE Ratio without NRI is 83.68. GT Biopharma's 5-Year EBITDA growth rate is 27.30%. Therefore, GT Biopharma's PEG Ratio for today is 3.07.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for GT Biopharma's PEG Ratio or its related term are showing as below:

FRA:OXIA' s PEG Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.22
Current: 0.22


During the past 13 years, GT Biopharma's highest PEG Ratio was 0.22. The lowest was 0.00. And the median was 0.00.


FRA:OXIA's PEG Ratio is ranked better than
92.63% of 95 companies
in the Biotechnology industry
Industry Median: 2.02 vs FRA:OXIA: 0.22

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


GT Biopharma  (FRA:OXIA) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


GT Biopharma PEG Ratio Related Terms


GT Biopharma PEG Ratio Historical Data

* Premium members only.

The historical data trend for GT Biopharma's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GT Biopharma PEG Ratio Chart

GT Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GT Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.09

FRA:OXIA vs INTI, HIND, TPST: PEG Ratio Comparison

For the Biotechnology subindustry, GT Biopharma's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GT Biopharma PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GT Biopharma's PEG Ratio distribution charts can be found below:

* The bar in red indicates where GT Biopharma's PEG Ratio falls into.


FRA:OXIA
21GF Score
GT Biopharma Inc FRA:OXIA
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GT Biopharma PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

GT Biopharma's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=83.684210526316/27.30
=3.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Frequently Asked Questions Learn more about PEG Ratio →
What does a PEG Ratio of 3.07 mean?
GT Biopharma (FRA:OXIA) has a PEG Ratio of 3.07 as of Jul. 05, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on GT Biopharma and its competitors. According to the industry distribution chart, GT Biopharma ranks #7 out of 95 companies in the Biotechnology industry, placing it in the top 7.4%.
Is GT Biopharma's PEG Ratio too high?
GT Biopharma's current PEG Ratio is 3.07. The Biotechnology industry median PEG Ratio is 2.02. GT Biopharma's value of 3.07 is 52% above this industry median. Based on the distribution chart, GT Biopharma ranks #7 out of 95 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, GT Biopharma has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does GT Biopharma's PEG Ratio compare to INTI and HIND?
According to the Biotechnology industry distribution chart, GT Biopharma ranks #7 out of 95 companies for PEG Ratio. This places GT Biopharma in the top 7% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 2.02. GT Biopharma's value of 3.07 is 52% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 2.02, based on 95 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GT Biopharma's current PEG Ratio of 3.07 is 52% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on GT Biopharma and its competitors. For the Biotechnology industry, the median PEG Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GT Biopharma's current PEG Ratio is 3.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GT Biopharma stock overvalued right now?
GT Biopharma (FRA:OXIA) has a current PEG Ratio of 3.07. The current PEG Ratio is 3.07 and 52% above the Biotechnology industry median of 2.02. GT Biopharma's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For GT Biopharma (FRA:OXIA), the current PEG Ratio is 3.07 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GT Biopharma Business Description

Other Exchanges GTBP:USA
Address 315 Montgomery Street, 10th Floor, San Francisco, CA, USA, 94104
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
21GF Score

Get the complete analysis for FRA:OXIA

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.77
Price